Role of Iron Isomaltoside 1000 in Treatment of Iron Deficiency Anemia in Obstetrics and Gynecological Patients
Vineet V Mishra, Rohina Aggarwal, Sumesh Choudhary, Kunur Shah, Smit B Solanki
Iron deficiency anemia, Iron isomaltoside 1000, Serum ferritin, hemoglobin
Citation Information :
Mishra VV, Aggarwal R, Choudhary S, Shah K, Solanki SB. Role of Iron Isomaltoside 1000 in Treatment of Iron Deficiency Anemia in Obstetrics and Gynecological Patients. J South Asian Feder Obs Gynae 2022; 14 (6):635-638.
Background: Pregnant women are particularly susceptible to iron deficiency anemia (IDA), a global health problem. Having an IDA is associated with poor outcomes for both the mother and the child. Due to the variety of laboratory tests available, the most commonly used are hemoglobin (Hb) and serum ferritin (SF). The standard treatment for IDA is intravenous (IV) iron.
Aim and objective: Iron isomaltoside (IIM) 1000 (Rapifer IV) treatment in pregnant and gynecological patients was evaluated in this study.
Materials and methods: Fifty pregnant women who were followed from the start of the second trimester until a few days before delivery were studied for IDA. For a minimum of 15 minutes, all women received the same dose of IIM 1000 mg (Rapifer IV). To determine the efficacy of the treatment plan, several tests were conducted, including estimations of Hb, red blood cell (RBC) count, white blood cell (WBC) count, platelet count, polymorphs, lymphocytes, eosinophils, monocytes, packed-cell volume (PCV), and mean corpuscular volume (MCV). When the ferritin level is 30 gm/L, severe iron deficiency (ID) is defined, while a mild-moderate ID is determined when the ferritin level is between 100 and 30 gm/L.
Results: Mean age of women with IDA was 35.14 ± 7.183 which ranged from 22 to 53 years. Significant improvement in mean Hb (8.64 ± 0.85 vs 12.86 ± 0.97, p <0.001), platelet count (115.11 ± 161.22 vs 3.13 ± 0.68, p < 0.001), polymorphs (70.9 ± 34.36 vs 50.62 ± 6.39, p = 0.0001), lymphocytes (32.24 ± 9.70 vs 39.68 ± 7.64, p = 0.0001), PCV (31.40 ± 4.46 vs 39.72 ± 2.56, p = 0.023), MCV (74.51 ± 8.23 vs 87.14 ± 3.05, p = 0.021), mean corpuscular hemoglobin (MCH) (23.71 ± 3.77 vs 31.62 ± 2.10, p = 0.012), mean corpuscular hemoglobin concentration (MCHC) (27.56 ± 2.81 vs 34.90 ± 2.30, p = 0.001), red cell distribution width (RDW) (18.48 ± 3.02 vs 13.94 ± 1.62, p = 0.004), total iron binding capacity (TIBS) (397.1 ± 74.53 vs 273.86 ± 31.55, p = 0.024), SF (32.19 ± 78.18 vs 85.96 ± 21.74, p <0.001), serum iron (46.40 ± 14.89 vs 108.32 ± 21.38, p <0.001), and reticulocytes (1.84 ± 0.79 vs 1.07 ± 0.29, p <0.001) after 27th day treatment with IIM 1000 compared to baseline. A significant improvement in Hb was observed in obstetrics and gynecological (12.68 from 8.24; p <0.001) and postoperative women (13.22 from 8.62; p <0.001). IIM 1000 was also able to improve severe ferritin level to mild-moderate ferritin level in a span of 27 days.
Conclusion: IIM 1000 (Rapifer IV) is efficacious in obstetrics and gynecological and postoperative women. A significant improvement was observed on the classical parameters of IDA.
Auerbach M, Deloughery T. Single-dose intravenous iron for iron deficiency: a new paradigm. Hematol Am Soc Hematol Educ Program 2016;2016(1):57–66. DOI: 10.1182/asheducation-2016.1.57.
Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One 2015;10(2):e0117383. DOI: 10.1371/journal.pone.0117383.
Wesström J. Safety of intravenous iron isomaltoside for iron deficiency and iron-deficiency anemia in pregnancy. Arch Gynecol Obstet 2020;301(5):1127–1131. DOI: 10.1007/s00404-020-05509-2.
Bircher AJ, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am 2014;34(3):707–723. DOI: 10.1016/j.iac.2014.04.013.
Szebeni J, Fishbane S, Hedenus M, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms, and management. Br J Pharmacol 2015;172(21):5025–5036. DOI: 10.1111/bph.13268.
Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis 2016;9:53–64. DOI: 10.2147/IJNRD.S89704.
Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens 2016;25(6):529–535. DOI: 10.1097/MNH.0000000000000263.
Bhandari S, Kalra PA, Berkowitz M, et al. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: The FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant 2021;36(1):111–120. DOI: 10.1093/ndt/gfaa011.
Chandra I, Sun L. Iron status and choice of iron therapy during pregnancy: advantages and disadvantages. Int J Reprod Contracept Obstet Gynecol 2015;4:1264–1271. DOI: 10.18203/2320-1770.ijrcog20150695.
Api O, Breyman C, Çetiner M, et al. Diagnosis and treatment of iron deficiency anemia during pregnancy and the postpartum period: Iron deficiency anemia working group consensus report. Turk J Obstet Gynecol 2015;12(3):173–181. DOI: 10.4274/tjod.01700.
Breymann C, Honegger C, Holzgreve W, et al. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet 2010;282(5):577–580. DOI: 10.1007/s00404-010-1532-z.
Pavord S, Myers B, Robinson S, et al. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol 2012;156(5):588–600. DOI: 10.1111/j.1365-2141.2011.09012.x.
Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 2016;31(4):646–655. DOI: 10.1093/ndt/gfv293.
Qassim A, Mol BW, Grivell RM, et al. Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: a systematic review. Aust N Z J Obstet Gynaecol 2018;58(1):22–39. DOI: 10.1111/ajo.12695.
Minogue A, Branstorm M, Westromm A, et al. Poster: consultant haematologist review of intravenous iron service in pregnant women at Queen's Hospital, Romford. Romford, UK: Transfusion Practitioner and Consultant Haematologist, Queen's Hospital; 2017.
Jahn MR, Andreasen HB, Futterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011;78(3):480–491. DOI: 10.1016/j.ejpb.2011.03.016.
Fell LH, Zawada AM, Rogacev KS, et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant 2014;29(4):809–822. DOI: 10.1093/ndt/gft524.
Fell LH, Zawada AM, Seiler S, et al. Impact of individual IV iron preparations on differentiation of macrophages and dendritic cells [poster FO014]: poster presented at 52nd Congress of ERA-EDTA; May 28–31, 2015; London, UK.